{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132838","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.840144+00:00","generated_at":"2026-05-20T03:10:19.551641+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"low","headline":"Kymera presents Phase 1 healthy volunteer data for oral STAT6 degrader KT-621","bullets":["Hosted conference call on June 2, 2025 to discuss Phase 1 results for KT-621, a first-in-class oral STAT6 degrader.","Slide presentation furnished as Exhibit 99.1; specific safety, PK/PD, or efficacy data not provided in available text.","KT-621 targets immuno-inflammatory diseases; Phase 1 study in healthy volunteers completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132838","json":"https://secwatch.observer/filing/0001193125-25-132838.json","markdown":"https://secwatch.observer/filing/0001193125-25-132838.md","text":"https://secwatch.observer/filing/0001193125-25-132838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525132838/0001193125-25-132838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525132838/d943327d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:10:19.551641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}